Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Other Manufacturing

Health

Manufacturing

Other Health

Polpharma Biologics

More Like This

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

PR Newswire associated0

Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development

PR Newswire associated0

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar